Evaluation of Herb–Drug Interactions of Hovenia dulcis Fruit Extracts

Jong Suk Park, Shaheed Ur Rehman, In Sook Kim, Min Sun Choi, Chun-Soo Na, Hye Hyun Yoo

Institute of Pharmaceutical Science and Technology and College of Pharmacy, Hanyang University, Ansan, ‘Lifetree Biotech Co., Ltd., Suwon, Gyeonggi-do, Republic of Korea

Submitted: 08-04-2016 Revised: 19-05-2016 Published: 18-04-2017

ABSTRACT

Background: Hovenia dulcis (Rhamnaceae) fruits are popularly used as herbal medicines or dietary supplements in Asian countries due to functions such as liver protection and detoxification from alcohol poisoning. Accordingly, it is very likely for dietary supplemental products, including H. dulcis fruit extracts, to be taken with prescription drugs. Objective: In this study, possible food–drug interactions involving H. dulcis fruit extracts were evaluated based on the inhibition of cytochrome P450 (CYP) enzyme activity. Material and Methods: The water extract of H. dulcis fruit extracts was incubated in human liver microsomes with CYP-specific substrates. The formation of the CYP-specific metabolites was measured using liquid chromatography-tandem mass spectrometry. Results: H. dulcis fruit extracts showed negligible effects on seven CYP isozyme activities at all concentrations tested. Conclusion: This result suggests that H. dulcis fruit extracts may have minimal pharmacokinetic interactions with coadministered drugs through the modulation of CYP enzymes.

Key words: Hovenia dulcis, Herb–drug interactions, CYP450, inhibition

SUMMARY

• Food-drug interactions involving H. dulcis fruit extracts were evaluated.
• The inhibition of CYPs by H. dulcis extracts was tested.
• H. dulcis extracts showed negligible effects on CYP activities.
• H. dulcis extracts may have minimal pharmacokinetic interactions with co-administered drugs.

INTRODUCTION

Herbal dietary supplements are receiving remarkable attention worldwide. Such products have traditionally been used as folk remedies and are liable to be regarded as safe.11 Herbal products are widely used to treat diseases and to improve individuals’ health in combination with prescription medicines.12 However, they are unregulated and many patients do not tell their physicians that they are taking herbal products. Therefore, there is growing concern about unexpected adverse effects induced by herb–drug interactions.13-16 One of the representative mechanisms of herb–drug interactions are alterations in the absorption and disposition of drugs via the modification of pharmacokinetic regulators, such as cytochrome P450 (CYP) enzymes.17 CYP enzymes are the major enzymes in the liver, which is a crucial organ for the drug metabolism of many conventional medicines.18,19 Many herbs could affect the enzyme activity of CYP, which may cause alterations in the metabolic clearance of the substrate drug by inhibiting or inducing a specific CYP enzyme; these modifications may lead to decreased therapeutic effects or increased toxicity of certain drugs.20,21 For these reasons, assessments of herb–drug interactions involving CYP inhibition based on in vitro data should be executed, in order to prevent adverse effects caused by taking prescription medicines in combination with herbal products.

Hovenia dulcis Thunberg belongs to a small genus of Rhamnaceae that occurs naturally in East Asia.22 This tree has been widely used as a traditional herb in Oriental medicine for many years, and the fruit stalk of H. dulcis is the main part of the tree that is used for herbal materials.12,13 The fruit stalks of H. dulcis have shown a variety of benefits, including alcohol detoxification,14,15 hepatoprotective effects,16,17 antioxidant effects,18 and antidiabetic effects.19,20 Therefore, the fruit stalk of H. dulcis has been popularly used as an herbal dietary supplement in Asian countries.21-24 H. dulcis products are mainly consumed as drinks, so it is very likely that they may be taken along with prescription or over-the-counter drugs. However, to our knowledge, information on the herb–drug interactions of H. dulcis fruit extracts has not yet been reported. Therefore, this study investigated the effects of fruit stalk extracts of H. dulcis on CYP-mediated drug metabolism using human liver microsomes, in order to assess and predict herb–drug interactions.
Table 1: CYP-specific marker substrates and their metabolites monitored

| CYP450 isozyme | Marker substrates | Concentration (µM) | Metabolites monitored | MRM ion transition |
|----------------|-------------------|-------------------|-----------------------|--------------------|
| CYP 1A2        | Phenacetin        | 40                | Acetaminophen         | 152.1>110.1        |
| CYP 2A6        | Coumarin          | 2.5               | 7-OH-Coumarin         | 162.9>106.9        |
| CYP 2C8        | Paclitaxel        | 10                | 6-OH-Paclitaxel       | 870.4>286.1        |
| CYP 2C9        | Diclofenac        | 10                | 4-OH-Diclofenac       | 312.2>230.9        |
| CYP 2C19       | (-)-Mephenytoin   | 80                | 4-OH-Mephenytoin      | 235.0>150.1        |
| CYP 2D6        | Dextromethorphan  | 5                 | Dextrophan            | 258.6>157.1        |
| CYP 3A4        | Midazolam         | 2.5               | 1-OH-Midazolam        | 343.1>325.1        |
|                |                   |                   | Terfenadine           | 472.4>436.4        |

**MATERIALS AND METHODS**

**Materials**

Aqueous extract samples of fruit stalks of *H. dulcis* were provided by Lifetree Biotech Co., Ltd. (Suwon, Korea). The extract was standardized to contain 0.88 ± 0.05 mg/g of ampelopsin and 0.86 ± 0.05 mg/g of taxifolin by HPLC analysis [Figure 1]. Pooled human liver microsomes were purchased from BD Gentest (Woburn, MA, USA). Glucose-6-phosphate, β-NADP⁺, glucose-6-phosphate dehydrogenase, phenacetin, coumarin, paclitaxel, diclofenac, mephenytoin, dextromethorphan, midazolam, furafylline, methoxsalen, sulfaphenazole, ticlopidine, quercetin, quinidine, ketoconazole, and terfenadine were obtained from Sigma Chemical Co. (St. Louis, MO, USA). Solvents for HPLC were purchased from J. T. Baker (Phillipsburg, NJ, USA). Distilled water was prepared using a MilliQ purification system (Millipore, Billerica, MA, USA).

**CYP inhibition assay**

The CYP inhibition assay was performed according to the previously published method.[23] Various concentrations of fruit stalk extracts from *H. dulcis* (1, 3, 10, 30, and 100 µg/mL in 70% methanol) were tested without and with a preincubation procedure, to test the possibility of mechanism-based inactivation. Well-known selective CYP inhibitors were used as positive controls. The inhibitors and their concentrations were as follows: 10 µM of furafylline for CYP1A2; 20 µM of methoxsalen for CYP2A6; 10 µM of quercetin for CYP2C8; 50 µM of sulfaphenazole for CYP2C9; 20 µM of ticlopidine for CYP2C19; 50 µM of quinidine for CYP2D6; and 5 µM of ketoconazole for CYP3A4. The resultant incubation samples were pretreated using solid-phase extraction, then analyzed based on multiple-reaction monitoring (MRM) detection using liquid chromatography-tandem mass spectrometry (LC-MS/MS). The CYP specific marker substrates used, and the metabolites monitored with their MRM precursor-product transition conditions, are tabulated in Table 1.

**High performance liquid chromatography (HPLC) analysis**

The content of the major bioactive constituents of *H. dulcis*, ampelopsin, and taxifolin was measured in the extract sample using HPLC. The HPLC analysis was performed based on the previously reported method.[26] The extract sample was dissolved in 80% methanol at a concentration of 250 mg/mL, filtered, and injected into the HPLC system. Ampelopsin and taxifolin were eluted at 6.2 and 10.8 min, respectively [Figure 1].

**RESULTS AND DISCUSSION**

The inhibitory effects of fruit stalk extract of *H. dulcis* were examined in human liver microsomes. The validity of the CYP assay system was assessed with well-known selective inhibitors of CYP isozymes: Furafylline (CYP1A2), methoxsalen (CYP2A6), quercetin (CYP2C8), sulfaphenazole (CYP2C9), ticlopidine (CYP2C19), quinidine (CYP2D6), and ketoconazole (CYP3A4). Each inhibitor selectively inhibited the corresponding CYP marker activity. The remaining activity of the CYP inhibitors was as follows: 2.79% for CYP1A2 (furafylline), 1.74% for CYP2A6 (methoxsalen), 6.64% for CYP2C8 (quercetin), 3.76% for CYP2C9 (sulfaphenazole), 16.57% for CYP2C19 (ticlopidine), 1.65% for CYP2D6 (quinidine), and 2.79% for CYP3A4 (ketoconazole) at designated concentrations. Tables 2 and 3 show the effect of fruit stalk

Table 2: Remaining activities of CYP isozymes following treatment with *H. dulcis* extracts (without preincubation)

| CYP450 isozyme | H. dulcis extract (µg/mL) | IC₅₀ (µg/mL) |
|----------------|--------------------------|-------------|
|                | 1            | 3            | 10           | 30           | 100          |
| CYP 1A2        | 107.0        | 99.1         | 90.9         | 93.0         | 96.6         | >100         |
| CYP 2A6        | 83.3         | 90.6         | 94.9         | 101.5        | 99.4         | >100         |
| CYP 2C8        | 97.6         | 92.2         | 80.1         | 112.1        | 82.6         | >100         |
| CYP 2C9        | 99.9         | 101.3        | 89.5         | 106.8        | 105.0        | >100         |
| CYP 2C19       | 81.2         | 89.2         | 87.5         | 83.6         | 105.2        | >100         |
| CYP 2D6        | 99.8         | 94.3         | 82.8         | 100.7        | 101.4        | >100         |
| CYP 3A4        | 90.9         | 98.0         | 87.8         | 103.6        | 102.3        | >100         |

*Data are shown as mean remaining activity (% of control) of duplicate measurements.

---

**Figure 1:** Representative HPLC chromatogram of *H. dulcis* fruit extracts. An Xbridge™ Shield RP18 column (4.6 mm I.D. x 150 mm, 3.5 µm) (Waters, Milford, USA) was used for the chromatographic separation. Column oven temperature maintained at 30°C. The mobile phase was composed of 0.1% acetic acid (solvent A) and acetonitrile (solvent B). The flow rate was 1.0 mL/min. The composition of solvent B was maintained at 20% for 3 min, linearly increased to 38% for 24 min, further increased to 90% for 1 min and maintained at 90% for 5 min, which was followed by equilibration to the initial composition for 6 min. The injection volume was 10 µL and the UV detection wavelength was 290 nm.
extracts of *H. dulcis* on the drug-metabolizing activity of seven CYP isozymes. When fruit stalk extracts of *H. dulcis* were tested without preincubation, no significant inhibitory effects on CYP isozyme enzyme activities were observed at any of the concentrations tested [Table 2]. When the fruit stalk extracts of *H. dulcis* were preincubated and tested, the extent of inhibition on several CYP isozyme activities was slightly different from the results shown in [Table 3], but no inhibitory effects on CYP isozyme enzyme activities were observed, and the IC50 values were all >100 μg/mL [Table 3]. Therefore, fruit stalk extracts of *H. dulcis* are considered to have negligible effects on drug metabolism regulated by CYP isozymes as competitive or mechanism-based inhibitors.

There have been several published reports demonstrating the CYP 450 inhibitory effects caused by the major bioactive compounds of *H. dulcis* extracts, ampepsin, and taxifolin. Huang et al. reported that ampepsin significantly inhibited CYP2C9 activity and induced CYP3A4 activity after oral administration in rats. Čelik et al. showed that taxifolin acts as a weak inhibitor of cytochrome b5 reductase, which is involved in specific CYP450-mediated drug metabolism by donating a second electron to CYP450 cytochrome b5. These previous reports raised some concerns about the possibility of inhibited CYP enzyme activity by *H. dulcis* extracts. However, in this study, no considerable inhibitory effects of *H. dulcis* extracts on CYP 450 enzymes were observed. It is supposed that the chemical complexity of *H. dulcis* extracts may compensate for or dilute the effects of ampepsin and taxifolin. The representative constituents of *H. dulcis* extracts are phenolic compounds and triterpene saponins. As phenolic compounds, hovenodulinol, hovenitins I, II, and III, (+)-3',3',5',5',7-pentahydroflavone, larcitrin, myricetin, (+)-gallocatechin, dihydrokaempferol, dihydroxyrutin (ampelopsin), and quercetin have been reported. Saponin C2, β-daucosterol, hovenidulciosides A1, A2, B1, and B2, hoolurosides I and III, and hovenidulcigenin have been reported as triterpene saponins. The property of each compound on CYP inhibition has not yet been fully elucidated. However, considering the content of ampepsin and taxifolin in the extract (less than 0.1%), the effect on CYP activity by these compounds in the extract is expected to be negligible as observed in this study.

**CONCLUSION**

The potential effects of fruit stalk extracts of *H. dulcis* on human CYP enzyme activities were evaluated *in vitro*, and the results showed a possible negligible interaction with coadministered drugs by the modulation of CYP enzymes. However, differences may exist between *in vitro* and *in vivo* test results. In addition, there could be other herb–drug interaction mechanisms involved with *H. dulcis* extracts and continued and further studies of such interactions should be conducted.

**Table 3:** Remaining activities of CYP isozymes following treatment with *H. dulcis* extracts (with preincubation)

| CYP450 isozyme | H. dulcis extract (μg/mL) | IC50 (μg/mL) |
|----------------|--------------------------|-------------|
|                | 1            | 3            | 10            | 30            | 100           | >100         |
| CYP 1A2        | 128.3        | 103.0        | 101.2         | 86.1          | 114.7         | >100         |
| CYP 2A6        | 116.7        | 119.1        | 115.0         | 95.0          | 91.7          | >100         |
| CYP 2C8        | 87.9         | 81.1         | 94.5          | 83.3          | 78.1          | >100         |
| CYP 2C9        | 92.0         | 97.1         | 107.6         | 94.9          | 96.0          | >100         |
| CYP 2C19       | 105.1        | 97.9         | 97.0          | 93.4          | 91.8          | >100         |
| CYP 2D6        | 90.8         | 102.7        | 106.3         | 96.8          | 91.7          | >100         |
| CYP 3A4        | 99.0         | 99.4         | 117.4         | 87.8          | 97.8          | >100         |

*Data are shown as mean remaining activity (% of control) of duplicate measurements.

This research was supported by Basic Science Research Program through the National Research Foundation of Korea funded by the Ministry of Education, Science and Technology (NRF-2014 R1A1A1A05002840).

**Conflicts of interest**

There are no conflicts of interest.

**REFERENCES**

1. Ziment I, Tashkin DP. Alternative medicine for allergy and asthma. J Allergy Clin Immunol 2000;106:603-14.
2. Wang J, Yang X, Feng B, Qian W, Fang Z, Liu W, et al. Is Yangxue Qingzhao Granule combined with anthihypertensive drugs, a new integrative medicine therapy: more effective than antihypertensive therapy alone in treating essential hypertension? Evid Based Complement Alternat Med 2013;2013:540-613.
3. Fasinu PS, Bouc PJ, Rosenkranz B. An overview of the evidence and mechanisms of herb-drug interactions. Front Pharmacol 2012;3:1-19.
4. Gouws C, Steyn DJ, Du Plessis L, Steenekamp J, Hamman JH. Combination therapy of Western drugs and herbal medicines: recent advances in understanding interactions involving metabolism and efflux. Expert Opin Drug Metab Toxicol 2012;8:973-84.
5. Sprouse AA, van Breemen RB. Pharmacokinetic interactions between drugs and botanical dietary supplements. Drug Metab Dispos 2016;44:162-71.
6. Gervasini G, Caballero MJ, Carrillo JA, Benitez J. Comparative cytochrome p450 in vitro inhibition by atypical antipsychotic drugs. ISRN Pharmacol 2013;2013:792456.
7. Kim J, Coss CC, Barrett CM, Mohler ML, Bohl CE, Li CM. Role and pharmacologic significance of cytochrome P-450 2D6 in oxidative metabolism of toremifene and tamoxifen. Int J Cancer 2013;132:1475-85.
8. Ueng YF, Ko HC, Chen CF, Wang JJ, Chen KT. Modulation of drug-metabolizing enzymes by extracts of a herbal medicine Evodia rutaecarpa in C57BL/6J mice. Life Sci 2002;71:1267-77.
9. Izzo AA, Di Carlo G, Borrelli F, Ernst E. Cardiovascular pharmacotherapy and herbal medicines: the risk of drug interaction. Int J Cardiol 2005;98:1-14.
10. Liu KH, Kim MJ, Jeon BH, Shin JH, Cha LJ, Choi KH. et al. Inhibition of human cytochrome P450 isoforms and NADPH-CYP reductase in vitro by 15 herbal medicines, including Epimedi herb. J Clin Pharm Ther 2006;31:89-91.
11. Gurley BJ, Swain A, Hubbard MA, Williams DK, Barone G, Hartsfield F, et al. Clinical assessment of CYP2D6-mediated herb-drug interactions in humans: Effects of milk thistle, black cohosh, goldenseal, kava kava, St. John’s wort, and Echinacea. Mol Nutr Food Res 2008;52:755-63.
12. Lim TK. Hovenia dulcis Edible medicinal and non-medicinal plants. Netherlands: Springer; 2013.p. 568-77.
13. Hyun TK, Eom SH, Yu CY, Rotisch T. Hovenia dulcis-an Asian traditional herb. Planta Med 2010;76:943-9.
14. Yoshiyama M, Murakami T, Ueda T, Yoshizumi S, Ninomiya K, Murakami N, et al. Bioactive constituents of Chinese natural medicines. III. Absolute stereostructures of new dihydroflavonols, hovenitins I, II, and III, isolated from hovenia semen fructus, the seed and fruit of Hovenia dulcis THUNB. (Rhamnaceae): inhibitory effect on alcohol-induced muscular relaxation and hepatoprotective activity. Yakugaku Zasshi 1997;117:108-18.
15. Chen SH, Zhong GS, Li AL, Li SH, Wu LK. Influence of Hovenia dulcis on alcohol concentration in blood and activity of alcohol dehydrogenase (ADH) of animals after drinking. Zhongguo Zhong Yao Za Zhi 2006;106:394-6.
16. Wang M, Zhu P, Jiang C, Ma L, Zhang Z, Zeng X. Preliminary characterization, antioxidant activity in vitro and hepatoprotective effect on acute alcohol-induced liver injury in mice of polysaccharides from the peduncles of Hovenia dulcis. Food Chem Toxicol 2012;50:2946-77.
17. Fang HL, Lin HY, Chan MC, Lin WL, Lin WC. Treatment of chronic liver injuries in mice by oral administration of ethanolic extract of the fruit of Hovenia dulcis. Am J Chin Med 2007;35:693-703.
18. Na CS, Yoon SY, Kim JB, Na DS, Dong MS, Lee MY, et al. Anti-fatigue activity of Hovenia dulcis on a swimming mouse model through the inhibition of stress hormone expression and antioxidation. Am J Chin Med 2013;41:945-55.
19. Ji Y, Chen S, Zhang K, Wang W. Effects of Hovenia dulcis Thunb on blood sugar and hepatic glycogen in diabetic mice. Zhong Yao Cai 2002;26:190-1.
20. Wu LH, Zhang J. Evaluation of anti-diabetic activities of Hovenia dulcis Thunb. Adv Mat Res 2012;554:1827-30.
21. Xiang J, Zhu W, Li Z, Ling S. Effect of juice and fermented vinegar from Hovenia dulcis peduncles on chronically alcohol-induced liver damage in mice. Food Funct 2012;3:628-34.
22. Park EM, Ye EJ, Kim SJ, Choi HI, Bae MJ. Eliminatory effect of health drink containing Hovenia dulcis Thunb extract on ethanol-induced hangover in rats. J Korean Soc Food Cult 2006;21:71-5.
23. Oh KH, Song HS. Sensory evaluation of seasoned soy sauce with hutgae (Hovenia dulcis Thunb) fruit and pear extracts. Korean J Food Nutr 2013;26:323-8.
24. Won SB, Song HS. Antioxidant activity and sensory evaluation in soy sauce with fruit, stem, or twig of Hovenia dulcis thunb. Korean J Food Nutr 2013;26:259-66.
25. Kim IS, Kim Y, Kwak TH, Yoo HH. Effects of β-lapachone, a new anticancer candidate, on cytochrome P450-mediated drug metabolism. Cancer Chemother Pharmacol 2013;72:699-702.
26. Park JS, Kim IS, Rehman SU, Na CS, Yoo HH. HPLC Determination of Bioactive Flavonoids in Hovenia dulcis Fruit Extracts. J Chromatogr Sci 2016;54:130-5.
27. Huang Y, Xu ZS, Ye Q. Effect of dihydromyricetin on cytochrome P450 isoforms CYP1A2, CYP2C9 and CYP3A4 in rats. Lat Am J Pharm 2013;32:1570-4.
28. Çelik H, Koşar M, Arınc E. In vitro effects of myricetin, morin, apigenin, (+)-taxifolin, (+)-catechin, (−)-epicatechin, naringenin and naringin on cytochrome b5 reduction by purified NADH-cytochrome b5 reductase. Toxicology 2013;308:34-40.